Daniel F. Heitjan

faculty photo
Senior Scholar, CCEB, University of Pennsylvania Perelman School of Medicine
Director of Biostatistics, Abramson Cancer Center, University of Pennsylvania
Department: Biostatistics and Epidemiology

Contact information
Department of Biostatistics & Epidemiology
University of Pennsylvania Perelman School of Medicine
622 Blockley Hall, 423 Guardian Drive
Philadelphia, PA 19104-6021
Office: (215) 573-7328
Fax: (215) 573-4865
Graduate Group Affiliations
B.Sc. (Mathematics)
University of Chicago, 1981.
(Applied Mathematics)
MIT, 1982.
M.Sc. (Statistics)
University of Chicago, 1984.
PhD (Statistics)
University of Chicago, 1985.
Permanent link

Description of Research Expertise

Clinical trials
Health economics
Incomplete data

Description of Itmat Expertise

Dr. Heitjan studies the theory of incomplete data, statistical methods in health economics, Bayesian methodology, the design and analysis of clinical trials, and methods for the analysis of smoking cessation trials. His work involves design and analysis of a range of basic, translational and clinical studies.

Selected Publications

Schwed Lustgarten DE, Thompson J, Yu G, Vachani A, Vaidya B, Rao C, Connelly M, Udine M, Tan KS, Heitjan DF, Albelda S.: Use of Circulating Tumor Cell Technology (CELLSEARCH®) for the Diagnosis of Malignant Pleural Effusions. Annals of the American Thoracic Society 10(6): 582-9, Dec 2013, In press Notes: Epub ahead of print.

Santen RJ, Song Y, Yue W, Wang JP, Heitjan DF. : Effects of menopausal hormonal therapy on occult breast tumors. The Journal of Steroid Biochemistry and Molecular Biology 137: 150-6, Sep 2013.

Elkassabany N., Ahmed M., Malkowicz S.B., Heitjan D.F., Isserman J.A., Ochroch E.A.: Comparison between the analgesic efficacy of transversus abdominis plane (TAP) block and placebo in open retropubic radical prostatectomy: a prospective, randomized, double-blinded study. J Clin Anesth 25(6): 459-65, Sep 2013.

Santen RJ, Yue W, Heitjan DF.: Occult breast tumor reservoir: biological properties and clinical significance. Hormones & Cancer 4(4): 195-207, Aug 2013.

Sohal DP, Metz JM, Sun W, Giantonio BJ, Plastaras JP, Ginsberg G, Kochman ML, Teitelbaum UR, Harlacker K, Heitjan DF, Feldman MD, Drebin JA, O'Dwyer PJ.: Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology 71(6): 1485-91, Jun 2013.

Ying GS, Heitjan DF.: Prediction of event times in the REMATCH Trial. Clinical Trials (London, England) 10(2): 197-206, Apr 2013.

Wileyto EP, Li Y, Chen J, Heitjan DF.: Assessing the fit of parametric cure models. Biostatistics 14(2): 340-50, Apr 2013.

Kang HC, Tan KS, Keefe SM, Heitjan DF, Siegelman ES, Flaherty KT, O'Dwyer PJ, Rosen MA.: MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. AJR Am J Roentgenol 200(1): 120-6, Jan 2013.

Nath K., Nelson D.S., Ho A.M., Lee S.C., Darpolor M.M., Pickup S., Zhou R., Heitjan D.F., Leeper D.B., Glickson J.D.: (31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan. NMR in Biomedicine 26(1): 98-105, Jan 2013.

Liu T, Heitjan DF.: Sensitivity of the discrete-time Kaplan-Meier estimate to nonignorable censoring: Application in a clinical trial. Stat Med 31(25): 2998-3010, Nov 2012.

back to top
Last updated: 09/24/2014
The Trustees of the University of Pennsylvania